Welcome to the ATTD 2023 Interactive Program

Session Description: This is the first of 3 education programs sponsored by Dexcom, Inc. at ATTD 2023, titled “Dexcom Continues to Lead in CGM Technology Across the Diabetes Spectrum.” and moderated by Dr. Daniel Chernavvsky. This education program will focus on Dexcom CGM and its use with both our Type 1 and Type 2 diabetes patients. Real world experience and correlational outcomes of Dexcom G7 and its unique features will be shared by Dr. Emma Wilmot, as well as an introduction to the new 2GO-CGM study, focusing on the use of Dexcom CGM use in Type 2, intensive and non-intensive insulin treated patients by the primary investigator, Dr. Martin de Bock. Finally, the next generation Dexcom-Type Zero AID algorithm and first in-human study results will be presented by Drs. Stephen Patek, Enrique Campos-Nanez, Martin de Bock and Katharine Barnard-Kelly. Finally, the next generation Dexcom-Type Zero AID algorithm and first in-human study results will be presented by Drs. Stephen Patek, Enrique Campos-Nanez, Martin de Bock and Katharine Barnard-Kelly.